349 related articles for article (PubMed ID: 25044635)
1. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
[TBL] [Abstract][Full Text] [Related]
2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
3. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
Wijns W; Vrolix M; Verheye S; Schoors D; Slagboom T; Gosselink M; Benit E; Donohoe D; Knape C; Attizzani GF; Lansky AJ; Ormiston J;
EuroIntervention; 2015 Apr; 10(12):1383-90. PubMed ID: 24801119
[TBL] [Abstract][Full Text] [Related]
4. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
5. Coronary vasomotion one year after drug-eluting stent implantation: comparison of everolimus-eluting and paclitaxel-eluting coronary stents.
Hamilos M; Ribichini F; Ostojic MC; Ferrero V; Orlic D; Vassanelli C; Karanovic N; Sarno G; Cuisset T; Vardas PE; Wijns W
J Cardiovasc Transl Res; 2014 Jun; 7(4):406-12. PubMed ID: 24794876
[TBL] [Abstract][Full Text] [Related]
6. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses.
Hamilos M; Sarma J; Ostojic M; Cuisset T; Sarno G; Melikian N; Ntalianis A; Muller O; Barbato E; Beleslin B; Sagic D; De Bruyne B; Bartunek J; Wijns W
Circ Cardiovasc Interv; 2008 Dec; 1(3):193-200. PubMed ID: 20031678
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of sirolimus-eluting stent versus bare metal stent evaluation of the coronary endothelial dysfunction in the same patient presenting with multiple coronary artery lesions: the CREDENTIAL study.
Mischie AN; Nazzaro MS; Fiorilli R; De Felice F; Musto C; Confessore P; Parma A; Boschetti C; Violini R
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E184-91. PubMed ID: 23359371
[TBL] [Abstract][Full Text] [Related]
8. Morphological, Functional, and Biological Vascular Healing Response 6 Months After Drug-Eluting Stent Implantation: A Randomized Comparison of Three Drug-Eluting Stents.
Nakata T; Fujii K; Fukunaga M; Shibuya M; Kawai K; Kawasaki D; Naito Y; Ohyanagi M; Masuyama T
Catheter Cardiovasc Interv; 2016 Sep; 88(3):350-7. PubMed ID: 26526816
[TBL] [Abstract][Full Text] [Related]
9. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
Hamilos MI; Ostojic M; Beleslin B; Sagic D; Mangovski L; Stojkovic S; Nedeljkovic M; Orlic D; Milosavljevic B; Topic D; Karanovic N; Wijns W;
J Am Coll Cardiol; 2008 Jun; 51(22):2123-9. PubMed ID: 18510958
[TBL] [Abstract][Full Text] [Related]
11. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
12. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
[TBL] [Abstract][Full Text] [Related]
13. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
[TBL] [Abstract][Full Text] [Related]
14. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
[TBL] [Abstract][Full Text] [Related]
15. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
[TBL] [Abstract][Full Text] [Related]
16. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials.
Wijns W; Vrolix M; Verheye S; Schoors D; Slagboom T; Gosselink M; Benit E; Kandzari D; Donohoe D; Ormiston JA
EuroIntervention; 2018 Apr; 13(18):e2147-e2151. PubMed ID: 29278354
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).
Lansky AJ; Kastrati A; Edelman ER; Parise H; Ng VG; Ormiston J; Wijns W; Byrne RA
Am J Cardiol; 2016 Feb; 117(4):532-538. PubMed ID: 26762729
[TBL] [Abstract][Full Text] [Related]
20. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
